Ticker
ABUS

Price
2.95
Stock movement up
+0.05 (1.72%)
Company name
Arbutus Biopharma Corp
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsværdi
464.63M
Ent værdi
498.90M
Pris/omsætning
12.91
Pris/bog
3.19
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
0.06%
Efterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års afkast
1.03%
3 års afkast
4.43%
5 års afkast
-10.37%
10 års afkast
-4.81%
Senest opdateret: 2023-02-02

UDBYTTE

ABUS betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF-
Pris til FCF0.02
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning12.91
Pris til egenkapital3.19
EV i forhold til salg13.87

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier157.50M
EPS (TTM)-0.46
FCF pr. aktie (TTM)136.30

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)35.98M
Bruttofortjeneste (TTM)35.98M
Driftsindkomst (TTM)-63.69M
Nettoindkomst (TTM)-68.84M
EPS (TTM)-0.46
EPS (1 år frem)-0.57

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)100.00%
Driftsmargin (TTM)-177.01%
Fortjenstmargin (TTM)-191.34%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter24.00M
Nettotilgodehavender6.42M
Omsætningsaktiver i alt141.14M
Goodwill0.00
Immaterielle aktiver0.00
Ejendomme, anlæg og udstyr0.00
Sum aktiver203.80M
Kreditor12.27M
Kortfristet/nuværende langsigtet gæld2.31M
Summen af kortfristede forpligtelser27.51M
Sum gæld58.28M
Aktionærernes egenkapital145.52M
Materielle nettoaktiver145.52M

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-17.35M
Investeringsudgifter (TTM)511.00K
Fri pengestrøm (TTM)20.58B
Udbetalt udbytte (TTM)12.14M

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-47.31%
Afkast af aktiver-33.78%
Afkast af investeret kapital-47.19%
Kontant afkast af investeret kapital14108.18%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning2.91
Daglig høj3.00
Daglig lav2.90
Daglig volumen529K
Højeste gennem alle tider30.94
1 års analytiker estimat5.40
Beta2.16
EPS (TTM)-0.46
Udbytte pr. aktie-
Ex-div dato-
Næste dato for resultatpræsentation2 Mar 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ABUSS&P500
Nuværende prisfald fra top notering-90.47%-12.75%
Højeste prisfald-97.19%-56.47%
Højeste efterår dato9 Oct 20199 Mar 2009
Gennemsnitlig fald fra toppen-71.63%-11.49%
Gennemsnitlig tid til nyt højdepunkt114 days13 days
Maks. tid til nyt højdepunkt2242 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
ABUS (Arbutus Biopharma Corp) company logo
Markedsværdi
464.63M
Markedsværdi kategori
Small-cap
Beskrivelse
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Personale
85
Investor relationer
-
SEC-indsendelser
Adm. direktør
William H. Collier
Land
USA
By
Warminster
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel...
27. januar 2023
Vericel Corporation (VCEL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...
12. januar 2023
Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into P...
5. januar 2023
Preliminary data from lead-in phase further validates AB-729’s capacity to reduce HBsAg Initial data from IFN phase expected in the first half of 2023 WARMINSTER, Pa., Dec. 13, 2022 (GLOBE NEWSWIRE) -...
13. december 2022
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
8. december 2022
Arbutus Biopharma ( NASDAQ:ABUS ) Third Quarter 2022 Results Key Financial Results Revenue: US$5.95m (up 78% from 3Q...
11. november 2022
Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 46.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
9. november 2022
Financially strong with a projected cash runway into the second quarter of 2024 HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729, o...
9. november 2022
WARMINSTER, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel...
8. november 2022
HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in c...
1. november 2022
Næste side